Skip to main content
. 2021 Sep 23;144(11):3392–3404. doi: 10.1093/brain/awab279

Table 3.

Clinical course and outcome of GBS in relation to SARS-CoV-2 infection

SARS-CoV-2 confirmed/probablea
Total (n =49) Yes (n =11) No (n =36) P-value
Mortality (%) 3/46 (7) 2 (18) 1/34 (3) 0.14
Mechanical ventilation (%) 9/47 (19) 4 (36) 5/34 (15) 0.19
 Days of ventilation (IQR) 17 (10–31) n =7 31 (17–31) n =2 11 (7–25) n =5 0.25
ICU admission (%) 13/47 (28) 6 (55) 7/34 (21) 0.05
 Days in ICU (IQR) 14 (3–31) n =12 28 (7–40) n =5 3 (3–24) n =7 0.09
Week 4
MRC sum score (IQR) 54 (32–60) n =30 49 (21–60) n =8 55 (41–60) n =22 0.28
GBS disability score (%)
 0–2 16/31 (52) 3/8 (38) 13/23 (57) 0.43
 3–4 12/31 (39) 3/8 (38) 9/23 (39) 0.94
 5 3/31 (10) 2/8 (25) 1/23 (4) 0.16
Week 13
GBS disability score (%)
 0–2 21/30 (70) 4/8 (50) 16/21 (76) 0.20
 3–4 6/30 (20) 2/8 (25) 4/21 (19) 0.72
 5 0 (0) 0 (0) 0 (0)
 6 3/30 (10) 2/8 (25) 1/21 (5) 0.18

Results are given as median (25th–75th percentile) or as counts (percentage). MRC sum = sum of Medical Research Council scores for muscle groups for shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension and ankle dorsiflexion of both limbs.

*

Significant values (P <0.05).

a

Classification by the ECDC case definitions. Unclassifiable patients (n =2) are not shown.